0001140361-24-036294.txt : 20240808 0001140361-24-036294.hdr.sgml : 20240808 20240808083540 ACCESSION NUMBER: 0001140361-24-036294 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240808 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240808 DATE AS OF CHANGE: 20240808 FILER: COMPANY DATA: COMPANY CONFORMED NAME: FEMASYS INC CENTRAL INDEX KEY: 0001339005 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 113713499 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40492 FILM NUMBER: 241186243 BUSINESS ADDRESS: STREET 1: 3950 JOHNS CREEK COURT STREET 2: SUITE 100 CITY: SUWANEE STATE: GA ZIP: 30024 BUSINESS PHONE: 770-500-3910 MAIL ADDRESS: STREET 1: 3950 JOHNS CREEK COURT STREET 2: SUITE 100 CITY: SUWANEE STATE: GA ZIP: 30024 8-K 1 ef20033802_8k.htm 8-K
 UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 8, 2024

Femasys Inc.
(Exact name of registrant as specified in its charter)
Delaware
001-40492
11-3713499
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)

3950 Johns Creek Court, Suite 100
Suwanee, Georgia
  
30024
(Address of principal executive offices)
  
(Zip Code)

(770) 500-3910
(Registrant’s telephone number, including area code)

n/a
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Exchange Act:
Title of each class
  
Trading
Symbol(s)
  
Name of each exchange
on which registered
Common Stock, par value $0.001 per share
   FEMY
  
The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Item 2.02
Results of Operations and Financial Condition.

On August 8, 2024, Femasys Inc. (the “Company”) announced its financial results for the quarter ended June 30, 2024 and provided a corporate update. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
 
The information in this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
 
Item 9.01
Financial Statements and Exhibits.
(d)
Exhibits.

Exhibit
No.
Description
   
Press Release of Femasys Inc. dated August 8, 2024
104
Cover Page Interactive Data File (embedded within the Inline XBRL Document)

SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
Femasys Inc.
 
By:
/s/ Kathy Lee-Sepsick
 
Names: Kathy Lee-Sepsick
 
Title: Chief Executive Officer
   
Date: August 8, 2024
  

 
 EX-99.1 2 ef20033802_ex99-1.htm EXHIBIT 99.1
Exhibit 99.1

Femasys Announces Financial Results for Quarter Ended June 30, 2024 and Provides Corporate Update
 
-- Company gained CE Mark approval for four of its women’s health products and completed buildout of commercial team for its infertility portfolio --
 
ATLANTA, August 8, 2024 -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible and innovative therapeutic and diagnostic products, announces financial results for the quarter ended June 30, 2024 and provides a corporate update.
 
Corporate Highlights from 2Q 2024 to date
 

 •
Company received European Union Medical Device Regulation (EU MDR) certification and CE Mark for four of its women’s health products, providing regulatory approval to begin marketing in the European Union. Further, it serves as independent validation of Femasys’ commitment to the highest standards of quality and safety for its customers and their patients.

•
Femasys completed the build-out of its initial commercial team in the U.S., which will be leading the Company’s marketing efforts. This milestone, together with the CE Mark approval for its product portfolio, enables Femasys to concurrently identify strategic distribution partners to begin commercialization of its products in the European Union.

•
CEO and Founder Kathy Lee-Sepsick met with the White House’s Gender Policy Council to discuss the Company’s reproductive health products and the future of women’s health in the United States and the White House’s Office of Science and Technology Policy to discuss the Cancer Moonshot Initiative, as well as separately with Members of Congress to raise awareness of the Company and our women’s healthcare initiatives.
 
“The recruitment and subsequent onboarding of our commercial team, consisting of highly qualified professionals with specific expertise in women’s health is complete and our team has recently begun actively marketing our products in the U.S.. We believe that our novel fertility solution FemaSeed®, which demonstrated pregnancy rates more than double the historic intrauterine insemination (IUI) pregnancy rates for male factor infertility (i.e., low sperm count), is an improved alternative and a viable option prior to in vitro fertilization (IVF) that is considerably more financially and emotionally burdensome. As we await announcement of published data for the FemaSeed prospective multi-center pivotal trial, we are actively prioritizing our U.S. efforts and concurrently identifying strategic distribution partners in Europe,” said Femasys’ CEO Kathy Lee-Sepsick.
 
Financial Results for Quarter Ended June 30, 2024
 

 •
Research and development expenses increased by $448,703 to $1,975,875 in Q2 of 2024 from $1,527,172 in Q2 of 2023.

•
Sales decreased by $99,030 to $221,484 in Q2 of 2024 from $320,514 in Q2 of 2023.

•
Net loss was $4,684,574 or ($0.21) per basic and diluted share attributable to common stockholders, for the quarter ended June 30, 2024, compared to net loss of $2,893,508, or ($0.22) per basic and diluted share attributable to common stockholders, for the quarter ended June 30, 2023.

•
Cash and cash equivalents as of June 30, 2024 was $13.5 million and the Company had an accumulated deficit of $116.7 million. The Company expects, based on its current operating plan, that its existing cash and cash equivalents will be sufficient to fund its ongoing operations into July 2025.
 
Financial Results for Six Months Ended June 30, 2024
 

 •
Research and development expenses increased by $681,995 to $3,746,606 for the first six months of 2024 from $3,064,611 for the first six months of 2023.

•
Sales decreased by $121,874 to $492,624 for the first six months of 2024 from $614,498 for the first six months of 2023.

•
Net loss was $8,284,084 or ($0.38) per basic and diluted share attributable to common stockholders, for the six month period ended June 30, 2024, compared to net loss of $5,839,765, or ($0.47) per basic and diluted share attributable to common stockholders, for the same period ended June 30, 2023.
 
For more information, please refer to the Company’s Form 10-Q filed August 8, 2024, which can be accessed on the SEC website.
 
PART I. FINANCIAL INFORMATION
ITEM I. Financial Statements

FEMASYS INC.
Condensed Balance Sheets
(unaudited)

Assets
  
June 30,
2024
    
December 31,
2023
  
Current assets:
            
Cash and cash equivalents
  
$
13,525,898
      
21,716,077
  
Accounts receivable, net
    
92,535
      
98,906
  
Inventory, net
    
1,315,580
      
667,118
  
Prepaid and other current assets
    
997,623
      
695,879
  
Total current assets
    
15,931,636
      
23,177,980
  
Property and equipment, at cost:
                
Leasehold improvements
    
1,212,417
      
1,212,417
  
Office equipment
    
47,308
      
47,308
  
Furniture and fixtures
    
429,933
      
414,303
  
Machinery and equipment
    
2,599,994
      
2,559,356
  
Construction in progress
    
651,157
      
423,077
  
     
4,940,809
      
4,656,461
  
Less accumulated depreciation
    
(3,678,450
)
    
(3,545,422
)
Net property and equipment
    
1,262,359
      
1,111,039
  
Long-term assets:
                
Lease right-of-use assets, net
    
2,081,054
      
2,380,225
  
Intangible assets, net of accumulated amortization
    
44,317
      
—
  
Other long-term assets
    
957,078
      
1,086,581
  
Total long-term assets
    
3,082,449
      
3,466,806
  
                 
Total assets
  
$
20,276,444
      
27,755,825
  

(continued)
 
FEMASYS INC.
Condensed Balance Sheets
(unaudited)
 
Liabilities and Stockholders’ Equity
  
June 30,
2024
    
December 31, 2023
  
Current liabilities:
            
Accounts payable
  
$
951,510
      
1,137,823
  
Accrued expenses
    
886,352
      
1,444,296
  
Clinical holdback – current portion
    
92,397
      
65,300
  
Lease liabilities – current portion
    
533,734
      
406,636
  
Total current liabilities
    
2,463,993
      
3,054,055
  
Long-term liabilities:
                
Clinical holdback – long-term portion
    
32,706
      
54,935
  
Convertible notes payable, net (including related parties)
    
4,758,017
      
4,258,179
  
Lease liabilities – long-term portion
    
1,771,487
      
2,036,067
  
Total long-term liabilities
    
6,562,210
      
6,349,181
  
Total liabilities
    
9,026,203
      
9,403,236
  
Commitments and contingencies
                
Stockholders’ equity:
                
Common stock, $.001 par, 200,000,000 authorized, 22,350,022 shares issued and 22,232,799 outstanding as of June 30, 2024; and 21,774,604 shares issued and 21,657,381 outstanding as of December 31, 2023
    
22,350
      
21,775
  
Treasury stock, 117,223 common shares
    
(60,000
)
    
(60,000
)
Warrants
    
2,608,642
      
2,787,137
  
Additional paid-in-capital
    
125,344,962
      
123,985,306
  
Accumulated deficit
    
(116,665,713
)
    
(108,381,629
)
Total stockholders’ equity
    
11,250,241
      
18,352,589
  
Total liabilities and stockholders' equity
  
$
20,276,444
      
27,755,825
  

The accompanying notes are an integral part of these condensed unaudited financial statements.
FEMASYS INC.
Condensed Statements of Comprehensive Loss
(unaudited)
 
   
Three Months Ended June 30,
    
Six Months Ended June 30,
  
   
2024
    
2023
    
2024
    
2023
  
Sales
  
$
221,484
      
320,514
      
492,624
      
614,498
  
Cost of sales (excluding depreciation expense)
    
73,125
      
110,469
      
161,657
      
215,589
  
                                 
Operating expenses:
                                
Research and development
    
1,975,875
      
1,527,172
      
3,746,606
      
3,064,611
  
Sales and marketing
    
975,190
      
128,899
      
1,275,677
      
373,795
  
General and administrative
    
1,611,817
      
1,356,637
      
3,114,621
      
2,671,774
  
Depreciation and amortization
    
67,628
      
133,299
      
138,856
      
266,365
  
Total operating expenses
    
4,630,510
      
3,146,007
      
8,275,760
      
6,376,545
  
Loss from operations
    
(4,482,151
)
    
(2,935,962
)
    
(7,944,793
)
    
(5,977,636
)
Other income (expense):
                                
Interest income
    
184,138
      
42,652
      
408,822
      
139,741
  
Interest expense
    
(388,311
)
    
(198
)
    
(749,863
)
    
(1,870
)
Total other income (expense), net
    
(204,173
)
    
42,454
      
(341,041
)
    
137,871
  
Loss before income taxes
    
(4,686,324
)
    
(2,893,508
)
    
(8,285,834
)
    
(5,839,765
)
Income tax benefit
    
(1,750
)
    
—
      
(1,750
)
    
—
  
                                 
Net loss
  
$
(4,684,574
)
    
(2,893,508
)
    
(8,284,084
)
    
(5,839,765
)
                                 
Net loss attributable to common stockholders, basic and diluted
  
$
(4,684,574
)
    
(2,893,508
)
    
(8,284,084
)
    
(5,839,765
)
Net loss per share attributable to common stockholders, basic and diluted
  
$
(0.21
)
    
(0.22
)
    
(0.38
)
    
(0.47
)
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted
    
22,215,516
      
13,107,590
      
21,995,436
      
12,493,334
  
 
The accompanying notes are an integral part of these condensed unaudited financial statements.

About Femasys
 
Femasys is a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic solutions, including a lead revolutionary product candidate and FDA-cleared products. FemaSeed® Intratubal Insemination, an innovative infertility treatment designed to deliver sperm directly where conception occurs, is FDA-cleared and has received regulatory approval in Canada and Europe. FemBloc® permanent birth control in late-stage clinical development is the first and only non-surgical, in-office, permanent birth control method intended to be a safer option for women at substantially less cost than the long-standing surgical alternative. The Company has developed diagnostic products that are complementary for which it has achieved regulatory approvals to market in the U.S., Canada, Europe and other ex-U.S. territories, and which are commercial-ready due to its in-house manufacturing capabilities. Its diagnostic products include FemVue® for fallopian tube assessment by ultrasound, which can be used in conjunction with FemCath®, an intrauterine catheter for selective fallopian tube evaluation, and FemCerv®, an endocervical tissue sampler for cervical cancer diagnosis. Learn more at www.femasys.com, or follow us on X, Facebook and LinkedIn.
 
Forward-Looking Statements
 
This press release contains forward-looking statements that are subject to substantial risks and uncertainties. Forward-looking statements can be identified by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “pending,” “intend,” “believe,” “suggests,” “potential,” “hope,” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on our current expectations and are subject to inherent uncertainties, risks and assumptions, many of which are beyond our control, difficult to predict and could cause actual results to differ materially from what we expect. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, among others: our ability to develop and advance our current product candidates and programs into, and successfully initiate, enroll and complete, clinical trials; the ability of our clinical trials to demonstrate safety and effectiveness of our product candidates and other positive results; estimates regarding the total addressable market for our products and product candidates; our ability to commercialize our products and product candidates, or the effect of delays in commercializing our products, including FemaSeed; our business model and strategic plans for our products, technologies and business, including our implementation thereof; and those other risks and uncertainties described in the section titled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2023, and other reports as filed with the SEC. Forward-looking statements contained in this press release are made as of this date, and Femasys undertakes no duty to update such information except as required under applicable law.

Contacts:

Investors:
Gene Mannheimer
IR@femasys.com

Media Contact:
Kati Waldenburg
Media@femasys.com


 EX-101.SCH 3 femy-20240808.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 femy-20240808_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Amendment Flag Document Fiscal Year Focus Document Fiscal Period Focus Document Period End Date Entity Registrant Name Entity Central Index Key Entity File Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Emerging Growth Company Entity Ex Transition Period Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name EX-101.PRE 5 femy-20240808_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Document and Entity Information
Aug. 08, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 08, 2024
Entity File Number 001-40492
Entity Registrant Name Femasys Inc.
Entity Central Index Key 0001339005
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 11-3713499
Entity Address, Address Line One 3950 Johns Creek Court
Entity Address, Address Line Two Suite 100
Entity Address, City or Town Suwanee
Entity Address, State or Province GA
Entity Address, Postal Zip Code 30024
City Area Code 770
Local Phone Number 500-3910
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol FEMY
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period true
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.2.u1 html 1 24 1 false 0 0 false 0 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://femasys.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports ef20033802_8k.htm femy-20240808.xsd femy-20240808_lab.xml femy-20240808_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ef20033802_8k.htm": { "nsprefix": "femy", "nsuri": "http://femasys.com/20240808", "dts": { "inline": { "local": [ "ef20033802_8k.htm" ] }, "schema": { "local": [ "femy-20240808.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2004/ref-2004-08-10.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/currency/2023/currency-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/exch/2023/exch-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd", "https://xbrl.sec.gov/sic/2023/sic-2023.xsd", "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" ] }, "labelLink": { "local": [ "femy-20240808_lab.xml" ] }, "presentationLink": { "local": [ "femy-20240808_pre.xml" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 3, "http://xbrl.sec.gov/dei/2023": 3 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 30, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://femasys.com/role/DocumentAndEntityInformation", "longName": "000100 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c20240808to20240808", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20033802_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20240808to20240808", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ef20033802_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r7" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://femasys.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 16 0001140361-24-036294-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001140361-24-036294-xbrl.zip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ef20033802_8k_htm.xml IDEA: XBRL DOCUMENT 0001339005 2024-08-08 2024-08-08 false 0001339005 NASDAQ 8-K 2024-08-08 Femasys Inc. DE 001-40492 11-3713499 3950 Johns Creek Court Suite 100 Suwanee GA 30024 770 500-3910 false false false false Common Stock, par value $0.001 per share FEMY true true